tbuckley/cabot-search huggingface dataset:
Abstract 14736: Association of Periarterial Low-Echoic Appearance with Progression of Coronary Allograft Vasculopathy and Long-Term Clinical Outcomes in Heart Transplant Patients
Authors: Hideki Kitahara, Kozo Okada, Hyoung-Mo Yang, Hong-Seok Lim, Kyuhachi Otagiri, Shigemitsu Tanaka, Yuhei Kobayashi, Paul G Yock, Alan C Yeung, Peter J Fitzgerald, Kiran K Khush, William F Fearon, Yasuhiro Honda
Journal: Circulation (2014)

Introduction:  Pathologic reports have indicated that cell-mediated rejection after heart transplant can affect the cardiac structures beyond the myocardium and coronary arteries. In clinical IVUS examination, a distinctive appearance of periarterial low-echoic area (PLEA) surrounding the coronary artery is observed in a substantial fraction of heart transplant recipients. This study aimed to evaluate the potential impact of this finding on early progression of cardiac allograft vasculopathy and long-term clinical outcomes.   Methods:  Serial IVUS was performed in 90 patients at early (1 month) and late (12 months) follow-up after heart transplantation. PLEA was defined as a low-echoic structure in the periarterial tissue with >1 mm in axial length, evaluated in the first 50 mm of the left anterior descending artery. The signal voids due to branches, veins, or myocardial bridging were excluded. The patients were stratified by the presence of acute-PLEA observed at 1 month and late-developed PLEA (late-PLEA) detected at 12 months.   Results:  Overall, 32% of patients had acute-PLEA, 27% developed late-PLEA, and 6% had both acute- and late-PLEA. Acute-PLEA was related to greater intima at 1 month (p   Conclusions:  The periarterial low-echoic appearance observed by IVUS, potentially reflecting perivascular edema or inflammation, is related to progression of cardiac allograft vasculopathy and possibly to adverse events after heart transplantation.
Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer: a Multi-Institution Study
Authors: J. Biagi, R. Burkes, C. Brezden-Masley, K. Zbuk, B. Meyers, O. Levine, S. Spadafora, S. Welch, S. Davdani, W. Hopman, C.M. Booth, R. Goodwin
Journal: Annals of Oncology (2014)
A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients
Authors: Paul J. Martin, Scott D. Rowley, Claudio Anasetti, Thomas R. Chauncey, Ted Gooley, Effie W. Petersdorf, Jo-Anne van Burik, Mary E.D. Flowers, Rainer Storb, Frederick R. Appelbaum, John A. Hansen
Journal: Blood (1999)
Web: Calculating the risk of disease
Authors: Giulio Bognolo
Journal: BMJ (2004)

Online tools for working out the risk of individual diseases are almost as old as the internet. The web is full of sites devoted to assessing people's risk of cardiovascular disease, for example. But now the Harvard Center for Cancer Prevention (part of Harvard School of Public Health) has produced a site designed to calculate the risk of five of the most important disease groups in the United States.

Launched last month, Your Disease Risk (www.yourdiseaserisk.harvard.edu) is an expanded version of the centre's cancer risk assessment website; in addition to the 12 cancers covered in the original site, it now also includes heart disease, stroke, diabetes, and osteoporosis.

The site is an interactive educational tool that seeks to encourage healthy lifestyles, making a quick and dirty assessment of people's eating, drinking, and exercise habits, and offering personalised tips for disease prevention. Visitors choose their “disease,” fill in an online questionnaire, and, assuming they don't lie, they should get a clear picture of their chances of being fit or sick in the future—or so the site claims.

The site began in the mid-1990s as a pen and paper risk assessment tool, and gradually evolved to its present format. Its contributors—epidemiologists, clinicians, and others from the Harvard medical community—identified established and probable risk factors for each disease based on the available scientific evidence. “This information was then used to develop calculations that generate a person's risk of disease compared to population averages by age and sex,” the site explains.

Your Disease Risk is extremely clear and user friendly. With quick links to other educational information from Harvard University, it is a serious attempt to guide people through the intricate world of disease prevention.

Naturally the media have already dubbed the site a “hypochondriac's dream,” but if the hits received by its predecessor site are anything to go by, there must a lot of hypochondriacs out there: Your Cancer Risk, launched in 2000, has averaged 900 to 1000 unique visitors daily for the past four years, making it Harvard School of Public Health's most successful website.
A randomized phase II trial of docetaxel plus S-1 versus docetaxel plus cisplatin in advanced gastric cancer as a first-line treatment
Authors: H. Jeung, C. Im, S. Rha, J. Ahn, S. Shin, S. Noh, J. Roh, H. Chung
Journal: Journal of Clinical Oncology (2008)

4534 Background: This randomized phase II trial evaluated two docetaxel-based regimens according to overall response rate (ORR) as first-line treatment of advanced gastric cancer with the aim to select a regimen for future phase III trial. Methods: Patients with measurable recurrent or metastatic gastric adenocarcinoma, a performance status ≤ 2, and adequate organ functions were randomly received docetaxel (35 mg/m2) on day 1 and day 8 plus S-1 (70 mg/m2/day) from day 1 to day 14 (DS), or the same dose of docetaxel plus cisplatin (35 mg/m2) on day 1 and day 8 (DC). The schedules were repeated every 3 weeks. Study endpoints included response rate (primary), survival, toxicity, and quality of life (QOL). Results: Eighty patients were enrolled and 76 patients were evaluable for response. Median number of cycles administered was 6 (range, 1–19) for DS, and 4 (range, 1–16) for DC. Median dose intensity was comparable in both arms. Confirmed ORR was 43.6% (95% CI, 27.3% to 59.9%) for DS arm (n = 39) and 24.3% (95% CI, 10.7% to 38.1%) for DC arm (n = 41) by intent-to-treat analysis. With the median follow-up duration of 264 days, median progression-free survival (PFS) was 198 and 143 days for DS and DC, respectively (p=0.03). Toxicity was acceptable, with one toxic death (DS arm). Grade 3–4 mucositis (12.8%) and hand-foot syndrome (10.2%) occurred more frequently in DS arm, while anorexia (17.1%) and fatigue (21.9%) were more frequent in DC arm. Global health status/QOL remained similar to baseline with both docetaxel regimens up to cycle 6. Conclusion: Both regimens were well tolerated and active in advanced gastric cancer. Based on the response rate and PFS, we advice DS regimen for further phase III trial. No significant financial relationships to disclose.
Feasibility Of αβT- Cell Depleted Allogeneic Stem Cell Transplantations From Matched Related and Unrelated Donor Grafts and Engraftment In Patients With Poor Risk Leukemia
Authors: Liane te Boome, Lotte van der Wagen, Kasper Westinga, Ineke Slaper-Cortenbach, Jurgen H Kuball
Journal: Blood (2013)
The telomerase template antagonist GRN163L reduces tumor volume in a multiple myeloma xenograft model
Authors: Server A. Ertem, Eunice Wang, Kaida Wu, Vladimir Ponomarev, Robert Tressler, Allison C. Chin, Malcolm A S Moore
Journal: Cancer Research (2005)

2840   Primary hematopoietic malignancies are characterized by short telomeres, suggesting that they would be acutely susceptible to telomerase inhibition. We have previously shown that treatment with a 13-mer thio-phosphoramidate oligonucleotide (GRN163, Geron Corporation), which binds specifically to the RNA template domain in the active site of telomerase, inhibits the growth of human multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) cell lines in vitro. The CAG MM cell line (TRF ∼ 2.7 Kb) was transfected with a retroviral vector encoding a triple fusion gene for HSV-TK, firefly luciferase and green fluorescence protein, and whole animal bioluminescence imaging was undertaken in either a subcutaneous or disseminated NOD/SCID model with extensive spinal cord and bone marrow tumor infiltration. Systemic daily treatment with GRN163 decreased tumor burden by 70% (Wang et al. Blood 2004; 103:258). GRN163L, a lipid-conjugated version of GRN163, showed enhanced cellular uptake and increased potency; telomerase activity was decreased by >90% (versus 40-80% with GRN163 at comparable doses) and apoptosis of tumor cells was increased. In a subcutaneous model with CAG, GRN163L was administered three times per week (tiw) at 30 mg/kg for 4 weeks alone or in combination with either a single dose of melphalan (5 mg/kg) or 9 doses of Velcade (0.25 mg/kg tiw). Tumor mass was reduced 56% with GRN163L alone (p
Evaluating the cost-effectiveness of the hospital-based palliative care program at The Johns Hopkins Hospital.
Authors: Sarina Isenberg, David R Holtgrave, Chunhua Lu, John P McQuade, Brian Weir, Natasha Gill, A. Rab Razzak, Thomas J. Smith
Journal: Journal of Clinical Oncology (2016)

23 Background: The objectives of the study were to determine whether a Palliative Care Unit (PCU) provides benefits not just from a cost perspective, but from a patient and caregiver quality of life (QOL) perspective. Methods: (1) Calculate the total costs of the PCU; (2) Leverage a threshold analysis to estimate the Quality-Adjusted Life Years (QALYs) required for the PCU to be cost effective; and (3) Determine whether it is feasible for the program to yield the required number of QALYs. Setting was the Johns Hopkins Health System Palliative Care Unit (PCU) in Baltimore, MD. Analysis was based on patient volume from March 2013-2014. Results: There were 209 palliative patients. The costs for the societal perspective was $2,044,364 and the required number of QALYs to deem it cost effective were 11.36. The net costs for the hospital perspective was $625,777 (gross cost was $993,528; however, the program generated $367,751 in savings for the hospital through treating patients in the PCU as opposed to other functional units), and the required number of QALYs to deem it cost effective were 3.48. To determine whether the program is able to achieve the number of QALYs required, the study team generated aggregated QALYs based on other studies’ evidence for palliative care’s improvement of quality of life for patients and their caregivers. Combining the QALYs generated from the aggregated calculations for patients (0.12) and caregivers (4.60), the program had the potential to yield a total of 4.73 QALYs. Conclusions: This analysis suggests that the PCU is cost effective from the hospital perspective in the sense that the benefits it provides to patients’ and caregivers’ quality of life outweighs the cost of care. Future studies should continue to evaluate palliative care from a cost effectiveness perspective that incorporates a consideration of the quality of life improvements, rather than just cost-reduction.
Serum Factor: The Inhibition of Phytohemagglutinin-Induced Blastogenesis of Chronic Lymphocytic Leukemia Lymphocytes2
Authors: T. M. Monahan, R. R. Fritz, C. W. Abell
Journal: JNCI Journal of the National Cancer Institute (1976)

A serum factor (SF), isolated from acidified sera of normal donors, inhibited phytohemagglutinin (PHA) stimulation of lymphocytes isolated from patients with chronic lymphocytic leukemia (CLL), but had no effect on those from healthy donors. An SF isolated by an identical procedure from the sera of patients with Cll had essentially no inhibitory effect on DNA synthesis in normal or leukemic lymphocytes. The SF was isolated from sera or plasma by ammonium sulfate precipitation, acidification to pH 1.5, and chromatography on DEAE-cellulose. The SF was heat labile and sensitive to digestion by trypsin. Maximum inhibition was obtained when the factor was added within 24 hours after the cells were stimulated with PHA.
Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping
Authors: Mauro Signorelli, Cinzia Crivellaro, Alessandro Buda, Luca Guerra, Robert Fruscio, Federica Elisei, Carlotta Dolci, Marco Cuzzocrea, Rodolfo Milani, Cristina Messa
Journal: Clinical Nuclear Medicine (2015)

Purpose The aim of this study was to evaluate the role of PET/CT and sentinel lymph node (SLN) biopsy in staging high-risk endometrial cancer patients (G2 and deep myometrial invasion, G3, serous clear cell carcinoma or carcinosarcoma) in early clinical stage. Patients and Methods From January 2006 to December 2012, high-risk early-stage endometrial cancer patients performing PET/CT scan followed by surgery (systematic pelvic ± aortic lymphadenectomy) were included. From December 2010, SLN mapping with 99mTc-albumin nanocolloid and blue dye cervical injection was included in our clinical practice and additionally performed. Histological findings were used as the reference standard. Results Ninety-three patients were included, of which 22 of 93 had both PET/CT and SLN biopsy. The median number of dissected lymph nodes (LNs) was 28. Nineteen women (20.4%) had pelvic LN metastases; 14 were correctly identified by PET/CT. Among 5 false-negative cases, 3 occurred after the introduction of SLN mapping due to detection of micrometastases by ultrastaging. On overall patient-based analysis, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for pelvic LN metastases were 73.7%, 98.7%, 93.6%, 93.3%, 93.6%, respectively. Conclusions PET/CT demonstrated moderate sensitivity and high specificity in detecting pelvic LN metastases; its high positive predictive value (93.3%) is useful to refer patients to appropriate debulking surgery. Sentinel LN mapping and histological ultrastaging increased the identification of metastases (incidence, 18.3%-27.3%) not detectable by PET/CT because of its spatial resolution. The combination of both modalities is promising for nodal staging purpose.
Practical Dietetics, With Reference to Diet in Disease
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pybus Collection
Authors: Wm. S. Mitchell
Journal: BMJ (1965)

Any Questions ?,O"L, 693(1 oz. to the pint of boiling water) is a wineglassful taken frequently."Schulz & Trier7 8 state that B. officfnalis contains several betaines which were formerly called betonicine.From these, true betonicine, which is laevorotatory, and turicine, which is its optical isomer and dextrorotatory, have been separated.The compounds have also been synthesized by methylating oxyproline.'The Merck Index states that the formula of betenicine is l-N,N-dimethyl-4-hydroxypyrrolidine-2-carboxylic acid betaine.It is said to be a compound with a sweet taste, but no action or use is given."0Mr. J. C.
Splenectomy in Leukemia and Leukosarcoma
Authors: John H. Fisher, C. Stuart Welch, William Dameshek
Journal: New England Journal of Medicine (1952)

THIS communication presents the results of splenectomy performed on patients with leukemia or leukosarcoma who have been followed in the Blood Clinic of the New England Medical Center during a period of approximately ten years (January 1, 1941, through December 31, 1950). It should be emphasized that removal of the spleen does not alter the fundamental malignant process; in the majority of patients with leukemia and leukosarcoma it is usually not advisable. This group of 18 patients with leukosarcoma and leukemia represents only 5 per cent of the patients subjected to splenectomy during the same ten-year period. The majority of . . .
What's it like to live with idiopathic pulmonary fibrosis? Ask the experts
Authors: Anne-Marie Russell, Jeffrey J. Swigris
Journal: European Respiratory Journal (2016)

Over the last 5–7 years, an enlightened paradigm has emerged for clinical research. In it, patients are not simply "subjects" to be studied or numbers to be analysed; more than "key stakeholders", patients are increasingly (and justly) recognised as the soul and substance of clinical investigation [1]. Patient advocacy organisations have added significant momentum to this movement by promoting patient-centred healthcare and helping to give a global voice to those who suffer from a range of conditions or impairments. Recent discussion on stratified medicine advocates the inclusion of patient perspectives and experience to inform the often complex decision-making processes regarding treatment [2]. Governing bodies and funding organisations have developed policies, programmes and agendas that have largely shaped the paradigm by fostering patient-centred investigations and advocating that studies be designed to ask and answer questions deemed important to patients, and include outcomes that are meaningful to patients [3]. Sharing and informing IPF healthcare decisions through partnerships with patients and their caregivers <http://ow.ly/YHp3X>
CI-FISH, GEP, and SNPs Correlate Genomic Categories with Risk Stratification in Children with T-ALL.
Authors: Roberta la Starza, Antonella Lettieri, Valentina Pierini, Caterina Matteucci, Valeria Nofrini, Paolo Gorello, Simona Songia, Barbara Crescenzi, Geertruy te Kronnie, Marco Giordan, Anna Leszl, Maria Grazia Valsecchi, Franco Aversa, Giuseppe Basso, Andrea Biondi, Valentino Conter, Giovanni Cazzaniga, Cristina Mecucci
Journal: Blood (2012)
Raltitrexed plus oxaliplatin and leucovorin modulated continuous 5-FU infusion (ROLF) in metastatic (MGC) and local advanced (LAGC) gastrointestinal cancer. A phase I / II study
Authors: E. J. Johnson-Buarque
Journal: Journal of Clinical Oncology (2004)

4267 Background: Raltitrexed (RX), oxaliplatin (OX) and 5-FU have shown synergistic and addictive activity against gastrointestinal cancer. The objective of the study was to evaluated the efficacy and toxicity of this combination and find the best oxaliplatin dose. Methods: Between april 2001 and april 2003 23 patients (pts) with MGC and LAGC (16 gastric and 7 colorectal cancer) were treated every 3 weeks with: day 1 RX 2,5 mg/m2, followed by OX 85 mg / m2 (after third cycle if no grade 3 or 4 toxicity increased to 100 mg/m2). 5-FU 1000 mg/m2 24hs continuos infusion, initiated after OX and lasted for 3 days modulated with leucovorin 50 mg each 6 hours. Pts: 13 male/10 female median age 64, 19 pts with more than one site of metastasis (mets). (9 pts with carcinomatosis and 9 with liver mets. Results: Toxicity: 5 pts experienced grade 3/4 stomatites and/or diarrhea. Only 2 pts with grade 3/4 leucopenia and 1 pt with neurotoxicity grade 3. Response: 19 pts were evaluated for response. CR-10.5% PR 52,5% SD- 21 % and Progr.16%. Median duration of response 7 months; median survival 16+ months, with 11 pts still alive. Conclusions: ROLF is an active scheme advanced gastric and colon cancer with low toxicity and in 40% pts a dose of 100 mg/m2 of OX is safe and could improve response. No significant financial relationships to disclose.
Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs).
Authors: Niall Christopher Tebbutt, Herbert Hurwitz, Fairooz Kabbinavar, Bruce J. Giantonio, Zhongzhen Guan, Lada Mitchell, Daniel Waterkamp, Josep Tabernero
Journal: Journal of Clinical Oncology (2012)

3614 Background: Bevacizumab (BV) with chemotherapy (CT) is a standard treatment for mCRC. This analysis pooled individual patient data from the clinical databases of seven RCTs (phase II or III) of BV in 1st- or 2nd-line treatment to further define clinical outcomes, including within subgroups. Methods: Patient data were pooled from 1st-line (AVF2107, NO16966, ARTIST, AVF2192, AVF0780, AGITG MAX) and 2nd-line (ECOG E3200) trials. All analyses were based on the intent-to-treat population. Overall and progression-free survival estimates (OS, PFS) were calculated by Kaplan-Meier methods. To assess differences in time to response variables by treatment arm (CT vs BV + CT), stratified random (overall) and fixed (subgroup comparisons) models were used to estimate pooled hazard ratios (HRs) and 95% confidence intervals (CIs), with each study included as a stratum. Results: Of the 3,763 pooled patients (CT [n=1773]; BV + CT [n=1990]), 58.8% were male, 39.6% were ≥65 years, and 45.7% had an ECOG performance status ≥1. OS and PFS were statistically significantly increased in BV-treated patients vs control patients. Safety data in this pooled analysis were consistent with the profile of BV from the individual studies. Conclusions: The addition of bevacizumab to CT resulted in statistically significant improvements in survival outcomes for mCRC patients in the overall analysis, with PFS benefit extending across subgroups defined by CT intensity, CT regimen, and KRAS status. [Table: see text]
Chemotherapy for malignant lymphoma patients. Oral care is necessary?
Authors: Kazuhiko Natori, Daisuke Nagase, Susumu Ishihara, Yurika Mitsui, Akiko Sakai, Motohiro Kato, Yasunobu Kuraishi, Kazuho Arai, Hideki Sekiya, Haruka Izumi
Journal: Annals of Oncology (2015)
Interim Results: Influenza A (H1N1) 2009 Monovalent and Seasonal Influenza Vaccination Coverage Among Health-Care Personnel — United States, August 2009-January 2010
Authors: Katherine M. Harris, Jürgen Maurer, C. F. Black, Gary Euler, C. W. LeBaron, J. A Singleton, A. E Fiore, T. F MacCannell
Journal: MMWR Morbidity and Mortality Weekly Report (2010)

Reports estimates of H1N1 and seasonal influenza vaccination rates among health care personnel in the United States, August 2009 - January 2010.